Ozempic

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Ozempic controls sugar in people with type 2 diabetes. Ozempic is a once-weekly injection.

Ozempic Overview

Reviewed: January 15, 2018
Updated: 

Ozempic is a prescription medication used to control blood glucose (sugar) in people with type 2 diabetes. 

Ozempic belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These control blood glucose (sugar) in people with type 2 diabetes by causing the pancreas to release insulin when blood sugar levels are high.

This medication comes in an injectable form in a prefilled pen. Ozempic is given just under the skin (subcutaneously), once weekly.

Common side effects of Ozempic include nausea, vomiting, and diarrhea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Ozempic Drug Class

Back to Top

Ozempic is part of the drug class:

Ozempic FDA Warning

Back to Top

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
  • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic.